ArticleCarcinogenesis2009
Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling.
Article in Carcinogenesis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Annexin A1: A Bane or a Boon in Cancer? A Systematic Review.Molecules (Basel, Switzerland) · 2020Pooled it
- Review
- Glyphosate and Aminomethylphosphonic Acid (AMPA) Modulate Glutathione S-Transferase in Non-Tumorigenic Prostate Cells.International journal of molecular sciences · 2023Article
- Annexin A1 Is Required for Efficient Tumor Initiation and Cancer Stem Cell Maintenance in a Model of Human Breast Cancer.Cancers · 2021Article
- Evaluation ofFood & nutrition research · 2021Article
- Construction of Potential Gene Expression and Regulation Networks in Prostate Cancer Using Bioinformatics Tools.Oxidative medicine and cellular longevity · 2021Article
- Seminal Plasma Proteome as an Indicator of Sperm Dysfunction and Low Sperm Motility in Chickens.Molecular & cellular proteomics : MCP · 2020Article
- Downregulation of C-Terminal Tensin-Like Protein (CTEN) Suppresses Prostate Cell Proliferation and Contributes to Acinar Morphogenesis.International journal of molecular sciences · 2018Article
- Annexin A1: Uncovering the Many Talents of an Old Protein.International journal of molecular sciences · 2018Review
- Article
- Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro.Molecular medicine reports · 2016Article
- Expression of NF-κB and IL-6 in oral precancerous and cancerous lesions: An immunohistochemical study.Medicina oral, patologia oral y cirugia bucal · 2016Article
- Article
- Annexin A1 in primary tumors promotes melanoma dissemination.Clinical & experimental metastasis · 2014Article
- Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.American journal of clinical and experimental urology · 2014Review
- Modelling gene expression profiles related to prostate tumor progression using binary states.Theoretical biology & medical modelling · 2013Article
- Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Current molecular medicine · 2013Review
- Computational investigation of intrinsic and extrinsic mechanisms underlying the formation of carcinoma.Mathematical medicine and biology : a journal of the IMA · 2012Article
- Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.The American journal of pathology · 2011Article
- Epigenetic transgenerational actions of vinclozolin on promoter regions of the sperm epigenome.PloS one · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Annexin A1 (ANXA1) expression is commonly reduced in premalignant lesions and prostate cancer, but a causal relationship of ANAX1 loss with carcinogenesis has not been established. ANXA1 levels have been shown to inversely correlate with interleukin 6 (IL-6) expression in other cell types and IL-6 has been suggested to enhance prostate cancer initiation and promotion. To investigate whether loss of ANXA1 may contribute to prostate carcinogenesis, ANXA1 expression was reduced using RNA interference in non-tumorigenic human prostatic epithelial cells (RWPE-1/rA1). No effect on morphology, apoptosis, migration or anchorage-dependent or -independent growth was detected. However, IL-6 mRNA and secreted protein levels were elevated in RWPE-1/rA1 cells. In addition, re-expression of ANXA1 in these cells suppressed IL-6 secretion, and altering ANXA1 levels in prostate cancer cells had similar effects on IL-6. The effects of ANXA1 loss and increased IL-6 expression on prostate epithelium were examined using an assay of acinar morphogenesis in vitro. Acini formed by RWPE-1/rA1 cells had delayed luminal clearing and larger mean diameters than control cells. The RWPE-1/rA1 phenotype was recapitulated by treating control cells with recombinant IL-6 and was reversed in RWPE-1/rA1 cells by blocking IL-6 bioactivity. Taken together, these data support a direct role for decreased ANXA1 expression in prostate carcinogenesis and enhancing tumor aggressiveness via the upregulation of IL-6 expression and activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.